SECONDARY ACUTE MYELOID LEUKEMIA
Clinical trials for SECONDARY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for SECONDARY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Tailoring chemo by genetics and health may boost survival in older AML patients
Disease control CompletedThis study tested whether matching chemotherapy intensity to a patient's genetic risk and overall health could improve outcomes for older adults (60+) with acute myeloid leukemia. 75 participants received either standard intensive or lower-intensity chemo based on their individua…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 23, 2026 19:32 UTC
-
New combo therapy shows promise for hard-to-treat leukemia
Disease control CompletedThis early-phase trial tested whether adding the drug uproleselan to standard chemotherapy (cladribine and low-dose cytarabine) could help people with treated secondary acute myeloid leukemia (AML). Secondary AML is a type of leukemia that develops after treatment for another bon…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 19:18 UTC
-
Experimental drug pair targets tough leukemias
Disease control CompletedThis early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 19:17 UTC
-
Experimental donor cell therapy shows promise for tough blood cancers
Disease control CompletedThis study tested a new treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) who had not responded to standard therapy. The treatment involved giving patients chemotherapy followed by an infusion of donor immune cells that had been sp…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
Can a bone marrow test predict who responds to a new AML combo?
Disease control CompletedThis study tested whether adding sirolimus (a drug that blocks cancer cell growth) to standard MEC chemotherapy improves outcomes in 39 patients with high-risk acute myeloid leukemia (AML). Researchers also checked if biomarkers in bone marrow samples could predict who would resp…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
Promising drug combo targets tough leukemia in early trial
Disease control CompletedThis early-phase study tested a two-drug combination (pevonedistat plus decitabine) in 12 people with high-risk acute myeloid leukemia (AML), including those who had relapsed or couldn't tolerate standard chemo. The main goal was to find the safest dose and identify side effects.…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
Could a Gene-Targeting drug boost chemo for older leukemia patients?
Disease control CompletedThis study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 12:02 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for kids with tough leukemia: experimental combo tested
Disease control CompletedThis early-phase study tested a combination of three chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or didn't respond to standard treatment. The main goals were to find the best dose and check for side effects. …
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
New liposome combo shows promise for Tough-to-Treat leukemia
Disease control CompletedThis study tested a new formulation of two chemotherapy drugs (CPX-351) in 56 adults with newly diagnosed acute myeloid leukemia (AML) who were at high risk of not responding to standard treatment. The goal was to find the best dose and see how well it worked to stop cancer cells…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 01, 2026 18:06 UTC
-
Gene study reveals clues to blood cancer outcomes
Knowledge-focused CompletedThis study followed 349 people newly diagnosed with myelodysplastic syndromes (MDS), a group of blood disorders that can lead to leukemia. Researchers used advanced DNA testing to find gene mutations and see how they affected survival and treatment response. The goal was to bette…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:46 UTC